More than two years has passed since the public health crisis caused by contaminated HP erupted. Despite numerous scientific studies from academic laboratories, industrial laboratories and government regulatory agencies, the exact identity and composition of the contaminants contained in suspect lots is still being debated [16, 40]. There are several reasons for the continued controversy. HP is a complex mixture that often contains complex impurities, such as DS. The putative contaminant, OSCS, is also a complex mixture of chains that can vary based on the MWavg of its CS precursor from as well as the completeness of its chemical sulfonation [7]. The small amount of OSCS contaminant (usually reported at 1-25% [42] relative to HP makes its isolation and identification difficult. OSCS also can inhibit heparin and chondroitin lyases [47] and thus care must be take to utilize sufficient amounts of highly active enzymes in the analysis HP and DS in samples containing OSCS. Finally, during the HP crisis there was a lack of sample control and record keeping required to definitively identify contemporaneous samples that actually were on the market in late 2007 to early 2008, administered to patients, and a cause of adverse reactions.